Novel Strategy to Enhance Human Mesenchymal Stromal Cell Immunosuppression: Harnessing Interferon-Gamma Presentation in Metal–Organic Frameworks Embedded on Heparin/Collagen Multilayers
Source abstract
Abstract
The immunomodulatory potential of human mesenchymal stromal cells (hMSCs) can be boosted when exposed to interferon-gamma (IFN-γ). While pretreating hMSCs with IFN-γ is a common practice to enhance their immunomodulatory effects, the challenge lies in maintaining a continuous IFN-γ presence within cellular environments. Therefore, in this research, we investigate the sustainable presence of IFN-γ in the cell culture medium by immobilizing it in water-stable metal-organic frameworks (MOFs) [PCN-333(Fe)]. The immobilized IFN-γ in MOFs was coated on top of multilayers composed of combinations of heparin (HEP) and collagen (COL) that were used as a bioactive surface. Multilayers were created by using a layer-by-layer assembly technique, with the final layer alternating between collagen (COL) and heparin (HEP). We evaluated the viability, differentiation, and immunomodulatory activity of hMSCs cultured on (HEP/COL) coated with immobilized IFN-γ in MOFs after 3 and 6 days of culture. Cell viability, compared to tissue culture plastic, was not affected by immobilized IFN-γ in MOFs when they were coated on (HEP/COL) multilayers. We also verified that the osteogenic and adipogenic differentiation of the hMSCs remained unchanged. The immunomodulatory activity of hMSCs was evaluated by examining the expression of indoleamine 2,3-dioxygenase (IDO) and 11 essential immunomodulatory markers. After 6 days of culture, IDO expression and the expression of 11 immunomodulatory markers were higher in (HEP/COL) coated with immobilized IFN-γ in MOFs. Overall, (HEP/COL) multilayers coated with immobilized IFN-γ in MOFs provide a sustained presentation of cytokines to potentiate the hMSC immunomodulatory activity.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Mesenchymal stem cell research · Immune cells in cancer · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Ralph E. Martin Department of Chemical Engineering, 3202 Bell Engineering Center, University of Arkansas, Fayetteville, Arkansas 72701, United States
Department of Biomedical Engineering, University of Arkansas, John A. White, Jr. Engineering Hall, 790 W. Dickson St. Suite 120, Fayetteville, Arkansas 72701, United States
Funding
National Science Foundation
References (58)
Show source-provided references
1. 10.1186/s12964-015-0124-810.1186/s12964-015-0124-8 ↗
2. 10.1016/j.semcdb.2007.09.01210.1016/j.semcdb.2007.09.012 ↗
3. 10.1038/s41536-019-0083-610.1038/s41536-019-0083-6 ↗
4. 10.1016/j.exphem.2004.02.00410.1016/j.exphem.2004.02.004 ↗
5. 10.32607/20758251-2012-4-1-23-3110.32607/20758251-2012-4-1-23-31 ↗
6. 10.1155/2017/329649810.1155/2017/3296498 ↗
7. 10.2174/18715280978846263510.2174/187152809788462635 ↗
8. 10.1038/nri239510.1038/nri2395 ↗
9. 10.1038/cddis.2015.32710.1038/cddis.2015.327 ↗
10. 10.1146/annurev-immunol-032712-09591910.1146/annurev-immunol-032712-095919 ↗
11. 10.1038/ni.300210.1038/ni.3002 ↗
12. 10.1038/nbt.281610.1038/nbt.2816 ↗
13. 10.1182/blood-2007-02-06971610.1182/blood-2007-02-069716 ↗
14. 10.1038/icb.2012.5610.1038/icb.2012.56 ↗
15. 10.1016/j.jcyt.2013.11.00810.1016/j.jcyt.2013.11.008 ↗
16. 10.1155/2013/73274210.1155/2013/732742 ↗
17. 10.1016/j.molmed.2011.10.00410.1016/j.molmed.2011.10.004 ↗
18. 10.1016/j.stem.2007.11.01410.1016/j.stem.2007.11.014 ↗
19. 10.1634/stemcells.2005-000810.1634/stemcells.2005-0008 ↗
20. 10.1073/pnas.161793311410.1073/pnas.1617933114 ↗
21. 10.1371/journal.pone.001469810.1371/journal.pone.0014698 ↗
22. 10.1021/acsbiomaterials.9b0000810.1021/acsbiomaterials.9b00008 ↗
23. 10.1016/j.mtbio.2021.10019410.1016/j.mtbio.2021.100194 ↗
24. 10.5966/sctm.2016-004410.5966/sctm.2016-0044 ↗
25. 10.1039/C7AY00710H10.1039/C7AY00710H ↗
26. 10.1039/C8DT01789A10.1039/C8DT01789A ↗
27. 10.1038/ncomms697910.1038/ncomms6979 ↗
28. 10.1021/jacs.5b0737310.1021/jacs.5b07373 ↗
29. 10.1016/j.jpba.2009.12.00410.1016/j.jpba.2009.12.004 ↗
30. 10.1039/D1MA00410G10.1039/D1MA00410G ↗
31. 10.1039/D0TB01454K10.1039/D0TB01454K ↗
32. 10.1021/acsbiomaterials.0c0139710.1021/acsbiomaterials.0c01397 ↗
33. 10.1002/jbm.a.3708510.1002/jbm.a.37085 ↗
34. 10.1021/acsbiomaterials.2c0103810.1021/acsbiomaterials.2c01038 ↗
35. 10.1007/s10439-019-02400-310.1007/s10439-019-02400-3 ↗
36. 10.1039/d0tb01454k10.1039/d0tb01454k ↗
37. 10.1021/acsami.0c0696410.1021/acsami.0c06964 ↗
38. 10.1002/admi.20160090510.1002/admi.201600905 ↗
39. 10.1021/bm020116i10.1021/bm020116i ↗
40. 10.1016/j.jcis.2012.08.00810.1016/j.jcis.2012.08.008 ↗
41. 10.1002/jbm.a.3282010.1002/jbm.a.32820 ↗
42. 10.1039/C4TB00448E10.1039/C4TB00448E ↗
43. 10.1016/S0021-9258(19)77982-410.1016/S0021-9258(19)77982-4 ↗
44. 10.3390/vaccines303070310.3390/vaccines3030703 ↗
45. 10.1016/0022-1759(94)90207-010.1016/0022-1759(94)90207-0 ↗
46. 10.1073/pnas.210597211810.1073/pnas.2105972118 ↗
47. 10.1016/S1369-5274(00)00199-510.1016/S1369-5274(00)00199-5 ↗
48. 10.1631/jzus.B160046010.1631/jzus.B1600460 ↗
49. 10.1126/scisignal.1.51.pe5510.1126/scisignal.1.51.pe55 ↗
50. 10.1002/eji.20114155010.1002/eji.201141550 ↗
51. 10.7150/ijbs.466610.7150/ijbs.4666 ↗
52. 10.1038/nri118410.1038/nri1184 ↗
53. 10.1146/annurev.immunol.26.021607.09035710.1146/annurev.immunol.26.021607.090357 ↗
54. 10.1016/j.jaci.2013.12.108810.1016/j.jaci.2013.12.1088 ↗
55. 10.1038/nri100110.1038/nri1001 ↗
56. 10.1146/annurev.immunol.19.1.42310.1146/annurev.immunol.19.1.423 ↗
57. 10.1586/1744666X.2015.102411010.1586/1744666X.2015.1024110 ↗
58. 10.1021/acs.bioconjchem.0c0033810.1021/acs.bioconjchem.0c00338 ↗